Pfizer's Litfulo Hits Endpoints in Nonsegmental Vitiligo Studies
By Colin Kellaher
Pfizer said a pair of late-stage studies of its Litfulo oral hair-loss drug met their key goals in the chronic depigmenting disorder nonsegmental vitiligo.
Pfizer on Thursday said the Phase 3 studies of Litfulo met their co-primary endpoints, with both the 50- and 100-milligram once-daily doses showing significant improvement in facial and total repigmentation versus placebo at 52 weeks in patients with both active and stable nonsegmental vitiligo who had a broad range of disease severity.
The New York drugmaker said that, based on the study results, it plans to submit global regulatory filings for Litfulo as a potential new oral systemic therapy for adults with nonsegmental vitiligo.
The U.S. Food and Drug Administration in 2023 approved Litfulo for the treatment of severe alopecia areata in people ages 12 and older.
Pfizer said it plans to launch a pivotal study evaluating Litfulo for the treatment of moderate alopecia areata this year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 30, 2026 08:03 ET (12:03 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States